Ernexa Therapeutics Inc. Contract Liability (Deferred Revenue)
Ernexa Therapeutics Inc. (ERNA) had Contract Liability (Deferred Revenue) of $5.33 million as of 2025-03-31, per its 10-Q filed 2025-05-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2025-05-07
- 2025-03-31: Contract with Customer, Liability, Current $5.33M.
- 2020-12-31: Contract with Customer, Liability, Current $76.00K.
- 2020-09-30: Contract with Customer, Liability, Current $120.00K.
- 2020-06-30: Contract with Customer, Liability, Current $377.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2025-03-31 | $5.33M 10-Q · filed 2025-05-07 |
| 2020-12-31 | $76.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $120.00K 10-Q · filed 2020-11-13 |
| 2020-06-30 | $377.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $383.00K 10-Q · filed 2020-05-20 |
| 2019-12-31 | $460.00K 10-K · filed 2020-03-19 |
| 2019-09-30 | $743.00K 10-Q · filed 2019-11-01 |
| 2019-06-30 | $518.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | $1.19M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $1.37M 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |